Similar articles

• Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.

  Crook ED, Preddie DC. Crook ED, et al. Ethn Dis. 2002 Fall;12(4):S3-49-52. Ethn Dis. 2002. PMID: 12477155
• ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner?

  Lewis EJ, Lewis JB. Lewis EJ, et al. J Am Soc Nephrol. 2004 May;15(5):1358-60. J Am Soc Nephrol. 2004. PMID: 15100380 Review. No abstract available.
• Diabetic nephropathy.

  Goto A. Goto A. N Engl J Med. 2002 Sep 19;347(12):947-8; author reply 947-8. doi: 10.1056/NEJM200209193471218. N Engl J Med. 2002. PMID: 12239270 No abstract available.
• ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.

  Kota SK, Meher LK, Jammula S, Kota SK, Modi KD. Kota SK, et al. Diabetes Metab Syndr. 2012 Oct-Dec;6(4):215-7. doi: 10.1016/j.dsx.2012.08.005. Epub 2012 Sep 7. Diabetes Metab Syndr. 2012. PMID: 23199543
• [Therapy of diabetic nephropathy].

  Barna I. Barna I. Orv Hetil. 2003 Jan 26;144(4):165-72. Orv Hetil. 2003. PMID: 12621814 Review. Hungarian.